Treatments for metastatic melanoma: Synthesis of evidence from randomized trials, Cancer Treatment Reviews, vol.33, issue.8, pp.665-80, 2007. ,
DOI : 10.1016/j.ctrv.2007.06.004
Dacarbazine-Mediated Upregulation of NKG2D Ligands on Tumor Cells Activates NK and CD8 T Cells and Restrains Melanoma Growth, Journal of Investigative Dermatology, vol.133, issue.2, pp.499-508, 2013. ,
DOI : 10.1038/jid.2012.273
URL : https://hal.archives-ouvertes.fr/inserm-00857892
Regulation of ligands for the activating receptor NKG2D, Immunology, vol.281, issue.4, pp.439-486, 2007. ,
DOI : 10.1016/S1535-6108(03)00110-7
Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100B, Clinical Cancer Research, vol.15, issue.16, pp.5208-5223, 2009. ,
DOI : 10.1158/1078-0432.CCR-09-0886
Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation, Experimental & Molecular Medicine, vol.38, issue.5, pp.474-8456, 2006. ,
DOI : 10.1038/emm.2006.56
Chemotherapy-Induced Genotoxic Stress Promotes Sensitivity to Natural Killer Cell Cytotoxicity by Enabling Missing-Self Recognition, Cancer Research, vol.70, issue.18, pp.7102-7115, 2010. ,
DOI : 10.1158/0008-5472.CAN-10-1316
ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype, Blood, vol.113, issue.15, pp.3503-3514, 2009. ,
DOI : 10.1182/blood-2008-08-173914
Immunological aspects of cancer chemotherapy, Nature Reviews Immunology, vol.313, issue.1, pp.59-73, 2008. ,
DOI : 10.1038/nri2216
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.8, pp.711-734, 2010. ,
DOI : 10.1056/NEJMoa1003466
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma, New England Journal of Medicine, vol.364, issue.26, pp.2517-2543, 2011. ,
DOI : 10.1056/NEJMoa1104621